Structural determinants of IGHV1-69 public antibodies conferring resilience to SARS-CoV-2 antigenic escape
Chuanying Niu, Xiaohan HuangiD, Qihong YaniD, Banghui LiuiD, Xijie GaoiD, Yidong SongiD, J. Y. Wang, Longyu Wang, Zimu LiiD, Huiran Zheng, Ping He, Xiaodong HuangiD, Hang YuaniD, Binqian Zou, Yuedong YangiD, Fandi WuiD, Yicheng Yao, Gul Habib, Xinwen CheniD, Ling Chen, Jun HeiD, Jianhua YaoiD, Jincun ZhaoiD, Xiaoli XiongiD
Abstract
R1-32-like public antibodies, characterized by shared IGHV1-69/IGLV1-40 usage, are elicited in more than 50% of individuals with COVID-19 and have been implicated in driving recurrent mutations at L452SARS2 and F490SARS2 within their convergent epitope in the SARS-CoV-2 spike receptor-binding domain. These mutations effectively mediate escape from non-affinity-matured R1-32-like antibodies with germline-like sequences. Here, we characterize four affinity-matured R1-32-like antibodies, C092, C807, BD56-104, and BD56-597, that tolerate L452SARS2 and F490SARS2 mutations. We show that this tolerance arises from residues introduced by somatic hypermutation at convergent positions across multiple CDR loops and surrounding regions, thereby creating additional contacts that reinforce epitope binding. An unusual N354SARS2 glycosylation site, which emerged in BA.2.86 and became fixed in its descendants, is linked to escape from affinity-matured R1-32-like antibodies, implying ongoing selection by this public antibody class. Using an AI model trained on integrated structural, neutralization, and binding data, we further identified ZL525, an ultrapotent R1-32-like antibody with pan-SARS-CoV-2 variant activity, including against the highly evasive KP.3 variant carrying the N354SARS2 glycosylation, and broad sarbecovirus cross-reactivity extending to SARS-CoV-1. Together, these findings show how affinity maturation enables public antibodies to adapt to viral antigenic drift, reveal their role in shaping SARS-CoV-2 antigenic evolution, and demonstrate the potential of AI-empowered strategies for discovering broadly neutralizing antibodies.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
- SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
M. McCallum, J. Bassi, … D. Veesler·bioRxiv·Mar 31, 2021
- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
M. Yuan, D. Huang, … I. A. Wilson·bioRxiv·Feb 16, 2021
- Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
F. Muecksch, Y. Weisblum, … P. Bieniasz·bioRxiv·Mar 7, 2021
- Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants
Naveenchandra Suryadevara, Seth J. Zost, … James E. Crowe·bioRxiv·Aug 20, 2026
- Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z. Liu, L. A. VanBlargan, … S. P. J. Whelan·bioRxiv·Nov 6, 2020